Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Fosphenytoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosphenytoin SCHEMBL20769774 | 1.00 | POLB (0.56) | POLBTDP1NPC1MEN1KMT2A | |
| Fosphenytoin SCHEMBL318673 | 0.99 | POLB (0.55) | POLBTDP1NPC1MEN1KMT2A | |
| Fosphenytoin SCHEMBL7205444 | 0.99 | POLB (0.55) | POLBTDP1NPC1MEN1KMT2A | |
| Fosphenytoin SCHEMBL1560790 | 0.99 | POLB (0.55) | POLBTDP1NPC1MEN1KMT2A | |
| Fosphenytoin SCHEMBL28132875 | 0.92 | POLB (0.49) | POLBTDP1NPC1MEN1KMT2A | |
| SCHEMBL2615240 | 0.92 | POLB (0.49) | POLBTDP1NPC1MEN1KMT2A | |
| Fosphenytoin SCHEMBL5798533 | 0.91 | CYP2C9 (0.52) | POLBTDP1NPC1MEN1KMT2A | |
| SCHEMBL18775360 | 0.89 | POLB (0.51) | POLBTDP1NPC1MEN1KMT2A | |
| SCHEMBL1725500 | 0.88 | POLB (0.55) | POLBTDP1NPC1MEN1KMT2A | |
| SCHEMBL8056128 | 0.87 | POLB (0.55) | POLBTDP1NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7490 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260048042-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | NEUROCRINE BIOSCIENCES INC (US) | 2026-02-19 | — | — | US | claimed |
| EP-4696377-A2 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of the University of California (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| US-12498384-B2 | Biomarkers and methods for evaluation and treatment of epileptic vs non-epileptic seizures / no seizures / psychogenic non-epileptic seizures | COGNIZANCE BIOMARKERS, INC. (US) | 2025-12-16 | — | — | US | claimed |
| EP-0986403-A1 | POLAR DRUG OR PRODRUG COMPOSITIONS WITH EXTENDED SHELF-LIFE STORAGE AND A METHOD OF MAKING THEREOF | Cydex Inc. (US) | 2000-03-22 | — | — | EP | claimed |
| WO-1999063984-A1 | NOVEL SODIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1999004798-A1 | LYOPHILIZED FOSPHENYTOIN SODIUM FOR PARENTERAL USE | WARNER-LAMBERT COMPANY (US) | 1999-02-04 | — | — | WO | claimed |
| WO-1998056422-A1 | POLAR DRUG OR PRODRUG COMPOSITIONS WITH EXTENDED SHELF-LIFE STORAGE AND A METHOD OF MAKING THEREOF | THE UNIVERSITY OF KANSAS (US) | 1998-12-17 | — | — | WO | claimed |
| EP-0746342-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD. (US) | 1996-12-11 | — | — | EP | claimed |
| US-5518730-A | Biodegradable controlled release flash flow melt-spun delivery system | FUISZ TECHNOLOGIES LTD. (US) | 1996-05-21 | — | — | US | claimed |
| EP-0746342-A4 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD (US) | 1996-01-11 | — | — | EP | claimed |
| WO-1993024154-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES, LTD. (US) | 1993-12-09 | — | — | WO | claimed |
| EP-0427925-A2 | Use of prophenytoin for preparing pharmaceutical preparations for treating stroke and cerebral ischemia | WARNER-LAMBERT COMPANY (US) | 1991-05-22 | — | — | EP | claimed |
| US-4260769-A | 5,5-Diphenylhydantoins | INTERX RESEARCH CORPORATION (US) | 1981-04-07 | — | — | US | claimed |